Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 24, 2020; 11(12): 1029-1044
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.1029
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.1029
Overall and cause-specific survival for mucoepidermoid carcinoma of the major salivary glands: Analysis of 2210 patients
Zachary C Taylor, Erin A Kaya, Zachary D Guss, Robert K Fairbanks, Wayne T Lamoreaux, Aaron E Wagner, Christopher M Lee, Department of Radiation Oncology, Cancer Care Northwest, Spokane, WA 99202, United States
Zachary C Taylor, Erin A Kaya, MD Program, Elson S. Floyd College of Medicine, Spokane, WA 99202, United States
Jeffrey D Bunn, Brian J Mitchell, Surgery, Spokane Ear, Nose, and Throat, Spokane, WA 99201, United States
Ben J Peressini, Department of Biostatistics, DataWorks Northwest, LLC, Coeur D'Alene, ID 83815, United States
Author contributions: Taylor ZC was the primary writing author, and contributed to data analysis and editing; Kaya EA, Bunn JD, Guss ZD, Mitchell BJ, Fairbanks RK, and Lamoreaux WT were responsible for data analysis and editing; Wagner AE and Peressini BJ contributed to biostatistics, data analysis and editing; Lee CM was the supervising author, and contributed to data analysis and editing.
Supported by Community Cancer Fund in Spokane , Washington, United States
Institutional review board statement: This retrospective clinical research project was exempt from Institutional Review Board review as de-identified information was utilized from the Surveillance, Epidemiology, and End Results (SEER) Database from the National Cancer Institute.
Informed consent statement: Informed consent was not obtained in this retrospective clinical research project as de-identified information was utilized from the Surveillance, Epidemiology, and End Results (SEER) Database from the National Cancer Institute.
Conflict-of-interest statement: The authors declare that there is no conflict of interest regarding the publication of this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Christopher M Lee, MD, Doctor, Department of Radiation Oncology, Cancer Care Northwest, 601 S. Sherman, Spokane, WA 99202, United States. lee@ccnw.net
Received: September 21, 2020
Peer-review started: September 21, 2020
First decision: October 21, 2020
Revised: November 5, 2020
Accepted: November 28, 2020
Article in press: November 28, 2020
Published online: December 24, 2020
Processing time: 88 Days and 5.7 Hours
Peer-review started: September 21, 2020
First decision: October 21, 2020
Revised: November 5, 2020
Accepted: November 28, 2020
Article in press: November 28, 2020
Published online: December 24, 2020
Processing time: 88 Days and 5.7 Hours
Core Tip
Core Tip: Mucoepidermoid carcinoma (MEC) of the major salivary glands is a rare cancer with a limited number of studies with high statistical power. The purpose of this study was to identify prognostic factors effecting overall survival (OS) and cause-specific survival (CSS) of individuals diagnosed with MEC of the major salivary glands. By using de-identified information from the Surveillance, Epidemiology and End-Results Program, we concluded that younger age at diagnosis, female sex, smaller tumor size, lower tumor grade, localized tumor growth, and more recent year of diagnosis were positive predictors of statistically significant improvements in OS and CSS.